The Role of EECP Therapy in Clinical Practice

The Role of EECP Therapy in Clinical Practice
Written by: Flow Therapy

This post is an excerpt from an article originally published in 2007 by the Journal of the American College of Cardiology. Click the link at the bottom to read the full article.

The Role of Enhanced External Counter Pulsation Therapy in Clinical Practice

Enhanced external counterpulsation (EECP) has been approved by the United States Food and Drug Administration (FDA) for management of refractory angina (Class IIb).

EECP uses three sets of pneumatic cuffs that sequentially contract during diastole, increasing aortic diastolic pressure, augmenting coronary blood flow and central venous return. EECP improves anginal symptoms and exercise tolerance, and reduces nitroglycerin use in patients with chronic, stable angina. EECP has also been shown to be safe and beneficial in patients with symptomatic stable congestive heart failure. It has been postulated that cardiac benefits of EECP are mediated though vascular endothelial growth factor (VEGF) and nitric oxide mediated vasodilatation and angiogenesis. In June 2002, the FDA also approved EECP therapy for heart failure patients.


More EECP Resources

A Practical Approach to Selecting EECP Patients

Over the past decade, the frequency of EECP therapy has increased in patients with angina.

Read More

Clinical Symptoms & Quality of Life After 35 Days of EECP Treatment

Clinical symptoms, quality of life, 6-minute walking distance, and more.

Read More

Beyond Medical Management: EECP for Angina & Heart Failure

The future of EECP stretches beyond medical management.

Read More